Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis

Bibliography

• Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70(6):896-904
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Annals of the rheumatic diseases. 2011;70(6):905-8
   Google Scholar
• van den Berg R, Stanislawska-Biernat E, van der Heijde DM. Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide. Rheumatology (Oxford) 2011;50(12):2270-7
   PubMed Web of Science ®Google Scholar
• Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2013; doi:10.1136/annrheumdis-2013-203419
   Web of Science ®Google Scholar
• van der Heijde D, Han C, DeVlam K, et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 2006;55(4):569-74
   PubMed Web of Science ®Google Scholar
• Braun J, McHugh N, Singh A, et al. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 2007;46(6):999-1004
   PubMed Web of Science ®Google Scholar
• Boonen A, Patel V, Traina S, et al. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 2008;35(4):662-7
   PubMed Web of Science ®Google Scholar
• Barkham N, Coates LC, Keen H, et al. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 2010;69(11):1926-8
   PubMed Web of Science ®Google Scholar
• Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011;70(4):590-6
   PubMed Web of Science ®Google Scholar
• Song IH, Weiss A, Hermann KG, et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis 2013;72:823-5
   PubMed Web of Science ®Google Scholar
• Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72(6):815-22
   PubMed Web of Science ®Google Scholar
• Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73(1):39-47
   PubMed Web of Science ®Google Scholar
• Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014;73(1):101-7
   PubMed Web of Science ®Google Scholar
• Sieper J, Lenaerts J, Wollenhaupt J, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 2014;73(1):108-13
   PubMed Web of Science ®Google Scholar
• Bisson-Vaivre A, Alcaix D, Zarnitsky C, et al. Efficacy of anti-TNF in patients with spondyloarthritis in absence of any imaging sign. Joint Bone Spine 2013;80(3):280-6
   PubMed Web of Science ®Google Scholar
• Spadaro A, Lubrano E, Marchesoni A, et al. Remission in ankylosing spondylitis treated with anti-TNF-alpha drugs: a national multicentre study. Rheumatology (Oxford) 2013;52(10):1914-19
   PubMed Web of Science ®Google Scholar
• Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013;72(7):1149-55
   PubMed Web of Science ®Google Scholar
• Paccou J, Bacle-Boutry MA, Solau-Gervais E, et al. Dosage adjustment of anti-tumor necrosis factor-alpha inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J Rheumatol 2012;39(7):1418-23
   PubMed Web of Science ®Google Scholar
• van Weely SF, van Denderen JC, Steultjens MP, et al. What do we miss? ASAS non-responders on anti-TNF therapy show improvement in performance-based physical function. Rheumatology (Oxford) 2013;52(10):1884-9
   PubMed Web of Science ®Google Scholar
• Furst DE, Kay J, Wasko MC, et al. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford) 2013;52(10):1845-55
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Braun J, Deodhar A, et al. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). Rheumatology (Oxford) 2013;52(2):321-5
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Deodhar A, Inman RD, et al. Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study. Arthritis Care Res 2012;64(12):1919-22
   Web of Science ®Google Scholar
• Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011;63(6):1543-51
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Braun J, Dougados M, et al. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. Rheumatology (Oxford) 2012;51(10):1894-905
   PubMed Web of Science ®Google Scholar
• Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68(1):18-24
   PubMed Web of Science ®Google Scholar
• Braun J, Pavelka K, Ramos-Remus C, et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol 2012;39(4):836-40
   PubMed Web of Science ®Google Scholar
• Chen JS, Makovey J, Lassere M, et al. Comparative effectiveness of anti-tumour necrosis factor (TNF) drugs on health-related quality of life among patients with inflammatory arthritis. Arthritis Care Res 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Shu T, Chen GH, Rong L, et al. Indirect comparison of anti-TNF-alpha agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials. Clin Exp Rheumatol 2013;31(5):717-22
   PubMed Web of Science ®Google Scholar
• Migliore A, Broccoli S, Bizzi E, Lagana B. Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials. J Med Econ 2012;15(3):473-80
   PubMedGoogle Scholar
• Zisman D, Haddad A, Hashoul S, et al. Hospitalizations of patients treated with anti-tumor necrosis factor-alpha agents – a retrospective cohort analysis. J Rheumatol 2013;40(1):16-22
   PubMed Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72(10):1605-12
   PubMed Web of Science ®Google Scholar
• Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013;72(10):1589-93
   PubMed Web of Science ®Google Scholar
• Viapiana O, Gatti D, Idolazzi L, et al. Bisphosphonates vs infliximab in ankylosing spondylitis treatment. Rheumatology (Oxford) 2014;53(1):90-4
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Jhangri GS, Fitzgerald AA, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46(3):766-73
   PubMed Web of Science ®Google Scholar
• Kiltz U, Heldmann F, Baraliakos X, Braun J. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr Opin Rheumatol 2012;24(3):252-60
   PubMed Web of Science ®Google Scholar
• van der Horst-Bruinsma IE, Zack DJ, Szumski A, Koenig AS. Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies. Ann Rheum Dis 2013;72(7):1221-4
   PubMed Web of Science ®Google Scholar
• Tournadre A, Pereira B, Lhoste A, et al. Differences between women and men with recent onset axial spondyloarthritis: Results from the DESIR cohort. Arthritis Care Res 2013;65(9):1482-9
   Web of Science ®Google Scholar
• Baraliakos X, Listing J, von der Recke A, Braun J. The natural course of radiographic progression in ankylosing spondylitis: differences between genders and appearance of characteristic radiographic features. Curr Rheumatol Rep 2011;13(5):383-7
   PubMedGoogle Scholar
• Dougados M, Braun J, Szanto S, et al. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. Rheumatology (Oxford) 2012;51(9):1687-96
   PubMed Web of Science ®Google Scholar
• Paramarta JE, De Rycke L, Ambarus CA, et al. Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment. Rheumatology (Oxford) 2013;52(10):1873-8
   PubMed Web of Science ®Google Scholar
• Paramarta JE, De Rycke L, Heijda TF, et al. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. Ann Rheum Dis 2013;72(11):1793-9
   PubMed Web of Science ®Google Scholar
• Paramarta JE, Heijda TF, Baeten DL. Fast relapse upon discontinuation of tumour necrosis factor blocking therapy in patients with peripheral spondyloarthritis. Ann Rheum Dis 2013;72(9):1581-2
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. Clin Exp Rheumatol 2013;31(4 Suppl 78):S33-6
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Kiltz U, Heldmann F, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. Clin Exp Rheumatol 2013;31(4 Suppl 78):S43-6
   PubMed Web of Science ®Google Scholar
• Song IH, Haibel H, Poddubnyy D, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol 2013;31(4 Suppl 78):S37-42
   PubMed Web of Science ®Google Scholar
• Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58(7):1981-91
   PubMed Web of Science ®Google Scholar
• Haibel H, Heldmann F, Listing J, et al. Long-term efficacy of adalimumab after drug withdrawal and retreatment of flare patients in active non-radiographic, axial spondyloarthritis. Arthritis Rheum 2013;65(8):2211-13
   PubMed Web of Science ®Google Scholar
• Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012;71(7):1212-15
   PubMed Web of Science ®Google Scholar
• Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2012;71(5):661-7
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann KG, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis 2012;71(6):878-84
   PubMed Web of Science ®Google Scholar
• Machado P, Landewe RB, Braun J, et al. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis 2012;71(12):2002-5
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years–early clinical response predicts long-term outcome. Rheumatology (Oxford) 2011;50(9):1690-9
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res The 2013;15(3):R67
   Google Scholar
• Durnez A, Paternotte S, Fechtenbaum J, et al. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study. J Rheumatol 2013;40(10):1712-18
   PubMed Web of Science ®Google Scholar
• Dischereit G, Tarner IH, Muller-Ladner U, Lange U. Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study. Clin Rheumatol 2013;32(3):377-81
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 2013. [Epub ahead of print]
   Google Scholar
• Baraliakos X, Braun J. Opinion: perspectives on imaging in axial spondyloarthritis. Nat Rev Rheumatol 2013;9(8):498-502
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73(4):710-5
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Heldmann F, Callhoff J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis 2013; doi: 10.1136/annrheumdis-2013-203425. [Epub ahead of print]
   Web of Science ®Google Scholar
• Baraliakos X, Listing J, Haibel H, et al. Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy. J Rheumatol 2013;40(11):1891-6
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Sieper J, Maksymowych WP, et al. Spinal inflammation in the absence of sacroiliac joint inflammation on MRI in patients with active non-radiographic axial spondyloarthritis. Arthritis Rheum 2013; doi:10.1002/art.38283. [Epub ahead of print]
   Web of Science ®Google Scholar
• Arends S, van der Veer E, Kallenberg CG, et al. Baseline predictors of response to TNF-alpha blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol 2012;24(3):290-8
   PubMed Web of Science ®Google Scholar
• Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011;70(6):973-81
   PubMed Web of Science ®Google Scholar
• Hu Z, Xu M, Li Q, et al. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis. Int J Rheum Dis 2012;15(4):358-65
   PubMed Web of Science ®Google Scholar
• Saad CG, Ribeiro AC, Moraes JC, et al. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 2012;14(5):R216
   PubMedGoogle Scholar
• Appel H, Ruiz-Heiland G, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009;60(11):3257-62
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012;64(5):1388-98
   PubMed Web of Science ®Google Scholar
• Wagner C, Visvanathan S, Braun J, et al. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Ann Rheum Dis 2012;71(5):674-80
   PubMed Web of Science ®Google Scholar
• Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72(12):1947-55
   PubMed Web of Science ®Google Scholar
• Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013;12(7):703-8
   PubMed Web of Science ®Google Scholar
• Plasencia C, Pascual-Salcedo D, Garcia-Carazo S, et al. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ther 2013;15(4):R79
   PubMed Web of Science ®Google Scholar
• Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis 2013; doi:10.1136/annrheumdis-2013-204195. [Epub ahead of print]
   Google Scholar
• Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72(Suppl 2):ii2-34
   PubMed Web of Science ®Google Scholar
• Hsia EC, Cush JJ, Matteson EL, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care Res 2013;65(2):309-13
   PubMed Web of Science ®Google Scholar
• Mariette X, Baron G, Tubach F, et al. Influence of replacing tuberculin skin test with ex vivo interferon gamma release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012;71(11):1783-90
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70(4):616-23
   PubMed Web of Science ®Google Scholar
• Pereira DF, Pinheiro MM, Silva PF, et al. Influence of TNF-alpha blockers on the oral prevalence of opportunistic microorganisms in ankylosing spondylitis patients. Clin Exp Rheumatol 2012;30(5):679-85
   PubMed Web of Science ®Google Scholar
• Toussirot E, Houvenagel E, Goeb V, et al. Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone spine 2012;79(5):457-63
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309(9):887-95
   PubMed Web of Science ®Google Scholar
• Serac G, Tubach F, Mariette X, et al. Risk of herpes zoster in patients receiving anti-TNF-alpha in the prospective French RATIO registry. J Invest Dermatol 2012;132(3 Pt 1):726-9
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301(7):737-44
   PubMed Web of Science ®Google Scholar
• Mathieu S, Pereira B, Couderc M, et al. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology (Oxford) 2013;52(1):204-9
   PubMed Web of Science ®Google Scholar
• Capkin E, Karkucak M, Kiris A, et al. Anti-TNF-alpha therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology (Oxford) 2012;51(5):910-14
   PubMed Web of Science ®Google Scholar
• Franca IL, Ribeiro AC, Aikawa NE, et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford) 2012;51(11):2091-8
   PubMed Web of Science ®Google Scholar
• Salinas GF, De Rycke L, Barendregt B, et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis 2013;72(6):1037-43
   PubMed Web of Science ®Google Scholar